Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Malignant Pleural Mesothelioma: Preliminary Toxicity Results of Adjuvant Radiotherapy Hypofractionation in a Prospective Trial (MESO-RT)

Title: Malignant Pleural Mesothelioma: Preliminary Toxicity Results of Adjuvant Radiotherapy Hypofractionation in a Prospective Trial (MESO-RT)
Authors: Parisi E.; Arpa D.; Ghigi G.; Fabbri L.; Foca F.; Tontini L.; Neri E.; Pieri M.; Cima S.; Burgio M. A.; Belli M. L.; Luzzi L.; Romeo A.
Contributors: Parisi E.; Arpa D.; Ghigi G.; Fabbri L.; Foca F.; Tontini L.; Neri E.; Pieri M.; Cima S.; Burgio M.A.; Belli M.L.; Luzzi L.; Romeo A.
Publication Year: 2023
Collection: IRIS Università degli Studi di Bologna (CRIS - Current Research Information System)
Subject Terms: hypofractionation; mesothelioma; OS; pulmonary cancer; radiation pneumoniti; radiotherapy; tomotherapy; toxicity
Description: Malignant Pleural Mesothelioma (MPM) is a rare malignancy with an overall poor prognosis. The standard therapeutic strategy in early-stage disease is trimodality therapy. In this publication, we report the preliminary toxicity results of the first 20 patients treated with accelerated hypofractionated radiotherapy. Between July 2017 to June 2019, 20 MPM patients were enrolled and treated with accelerated hypofractionated radiotherapy using helical tomotherapy and intensity-modulated arc therapy. The prescription dose was 30 Gy in five daily fractions, while an inhomogeneous dose escalation to 40 Gy was prescribed based solely upon the presence of gross residual tumor. Only one case of G3 toxicity was reported, which was a bilateral pneumonitis that occurred two years after treatment probably due to superinfection. Median Time to Progression reached 18.2 months while one- and three-year Overall Survival rates were 85% (95% CI:60.4–94.9) and 49.5% (95% CI:26.5–68.9), respectively. Treatment of the intact lung with pleural intensity-modulated arc irradiation is a novel treatment strategy that appears to be safe, feasible, and without a high grade of lung toxicity. Survival rates and Time to Progression are encouraging.
Document Type: article in journal/newspaper
File Description: ELETTRONICO
Language: English
Relation: info:eu-repo/semantics/altIdentifier/pmid/36831400; info:eu-repo/semantics/altIdentifier/wos/WOS:000944840900001; volume:15; issue:4; firstpage:1; lastpage:12; numberofpages:12; journal:CANCERS; https://hdl.handle.net/11585/965888
DOI: 10.3390/cancers15041057
Availability: https://hdl.handle.net/11585/965888; https://doi.org/10.3390/cancers15041057; https://www.mdpi.com/2072-6694/15/4/1057
Rights: info:eu-repo/semantics/openAccess
Accession Number: edsbas.EA87AB74
Database: BASE